zidovudine + adefovir

This is a **combination of zidovudine and adefovir**. **Zidovudine** is a synthetic nucleoside analog (specifically a thymidine analog), classified as a nucleoside reverse transcriptase inhibitor (NRTI). Zidovudine is phosphorylated intracellularly to an active triphosphate form, which is incorporated into viral DNA by HIV reverse transcriptase, resulting in chain termination and inhibition of viral replication[1][2][4][6]. **Adefovir (usually administered as adefovir dipivoxil)** is a nucleotide analog (acyclic analogue of adenosine monophosphate), classified as a nucleotide reverse transcriptase inhibitor (NtRTI). After cellular conversion to its active diphosphate form, it inhibits viral DNA polymerase (reverse transcriptase), causing DNA chain termination, and has been used primarily for hepatitis B virus (HBV) infection[3]. There is limited to no evidence that such a combined formulation (zidovudine + adefovir) is in clinical use or has a marketed product; this is a hypothetical or research-use combination, not a recognized commercial product. Both agents are **small molecule antiretroviral drugs**. Zidovudine is developed by Burroughs Wellcome (now part of GSK/Viiv Healthcare). Adefovir dipivoxil was developed by Gilead Sciences.

Brand names

Retrovir (zidovudine)Hespera (adefovir dipivoxil)

Other names

azidothymidine (zidovudine)zidovudinazidovudinum